Gabelli & CO Investment Advisers, Inc. Revance Therapeutics, Inc. Transaction History
Gabelli & CO Investment Advisers, Inc.
- $518 Million
- Q4 2024
A detailed history of Gabelli & CO Investment Advisers, Inc. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Gabelli & CO Investment Advisers, Inc. holds 1,058,500 shares of RVNC stock, worth $2.72 Million. This represents 0.53% of its overall portfolio holdings.
Number of Shares
1,058,500
Previous 839,800
26.04%
Holding current value
$2.72 Million
Previous $2.16 Million
26.04%
% of portfolio
0.53%
Previous 0.4%
Shares
2 transactions
Others Institutions Holding RVNC
# of Institutions
219Shares Held
77.6MCall Options Held
2.18MPut Options Held
5.27M-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Beryl Capital Management LLC Redondo Beach, CA5.94MShares$15.3 Million9.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.63MShares$14.5 Million0.0% of portfolio
-
Oddo Bhf Asset Management Sas Paris, I05.1MShares$13.1 Million0.78% of portfolio
-
Fil LTD Hamilton, D04.2MShares$10.8 Million0.01% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...